Precision BioSciences Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Precision BioSciences, Inc. on May 31, 2022. The report discloses corporate governance changes effective May 26, 2022, specifically regarding the appointment of a new director and committee chair.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and compensation arrangements rather than financial performance.
Material Changes
The primary material change reported is the appointment of Melinda Brown to the Board of Directors as a Class III director and as Chair of the Audit Committee. This appointment is effective as of May 26, 2022.
Compensation and Governance Details
- Board Retainer: $40,000 annual cash retainer, earned quarterly.
- Audit Committee Chair Retainer: $15,000 annual cash retainer, earned quarterly.
- Initial Equity Award: Options with an aggregate grant date fair value of $400,000, vesting over 36 months.
- Annual Equity Award: Options with an aggregate grant date fair value of $200,000, granted at the annual meeting (subject to service requirements), vesting on the earlier of the first anniversary or the day prior to the next annual meeting.
- Term: Ms. Brown's term expires at the 2025 annual meeting of stockholders.
Key Facts for Investor Verification
- Verify the impact of the new Audit Committee Chair on the company's financial oversight and internal controls.
- Confirm the total equity dilution associated with the $400,000 initial grant and future $200,000 annual grants.
- Review the press release (Exhibit 99.1) for additional context on Ms. Brown's qualifications and background.
- Note that this filing does not contain updated financial results; refer to the most recent 10-Q or 10-K for financial data.